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Abstract
Background/purpose—Tumor heterogeneity is a now well-recognized phenomenon that can 
affect the classification, prognosis and treatment of human cancers. Heterogeneity is often 
described in primary breast cancers based upon histologic subtypes, hormone- and HER2-receptor 
status, and immunolabeling for various markers, which can be seen within a single tumor as mixed 
cellular populations, or as separate discrete foci.
Experimental Design/Methods—Here we present a case report of a patient’s primary breast 
cancer that had two separate but adjacent histologic components, one that was estrogen receptor 
(ER) positive, and the other ER negative. Each component was subjected to whole exome 
sequencing and compared for gene identity to determine clonal origin.
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Results—Using prior bioinformatic tools, we demonstrated that both the ER positive and 
negative components shared many variants, including passenger and driver alterations. Copy 
number variations also supported the two components were derived from a single common clone.
Conclusions—These analyses strongly suggest that the two ER components of this patient’s 
breast cancer were derived from the same clonal origin. Our results have implications for the 
evolution of breast cancers with mixed histologies, and how they might be best managed for 
optimal therapy.
Keywords
whole exome sequencing; breast cancer; estrogen receptor
Introduction
Breast cancer is not a single disease but a heterogeneous group of diseases with a broad 
range of clinical features, prognoses and treatment responses. Clinically, immunostaining 
remains the standard of care for assessing the presence of estrogen receptor-alpha (ER), 
progesterone receptor (PR) and HER2 within the primary tumor, with additional in situ 
hybridization testing for HER2 assessment when indicated [1]. The presence or absence of 
ER/PR and HER2 determines candicacy for endocrine therapies and HER2 directed 
therapies, respectively. Based on gene expression profiling, primary breast cancers can be 
further refined as luminal, HER2-like, or basal, which may have implications for treatment 
indications, progression and prognosis [2].
Recent evidence has demonstrated that tumor heterogeneity within a primary tumor is 
common [3] and may have clinical importance. For example, a fundamental question that 
often arises in clinical breast oncology is whether patients with discrete foci have polyclonal 
or monoclonal disease. This is often in the context of having multi-focal/multi-centric 
disease, or bilateral tumors, but with concordant receptor subtypes, leading to the quandary 
of whether these cancers share a common origin. With newer prognostic/predictive tests 
such as Oncotype DX, which analyzes a limited gene expression panel, heterogeneity among 
multiple foci could influence the decision to administer chemotherapy, depending if single 
vs. multiple sites of disease are tested [4]. On the other hand, when receptor subtypes are 
discordant, e.g. an ER positive tumor along with a separate focus of an ER negative tumor, it 
is generally thought that these tumors are from distinct clonal populations.
Tumor heterogeneity for many primary breast cancers is also seen within a single tumor 
mass, where varying percentage of cells and strength of labeling is seen by immunostaining 
for ER, PR and HER2. Here too, clinical management may be influenced by the amount and 
intensity of receptors present. For example, a breast cancer that has weak ER labeling in 5% 
of all cancer cells, may not derive as much benefit from endocrine therapies, and may 
influence the decision to recommend adjuvant chemotherapy. Oftentimes cases with variable 
receptor expression show cellular populations that are ER positive admixed with ER 
negative cells but do not demonstrate discrete focal areas of receptor positivity within the 
primary tumor mass. Here we present an unusual case report of a primary breast cancer 
containing two separate but adjacent ER positive and ER negative areas. We have previously 
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shown using microdissection and whole exome sequencing (WES) that primary breast 
cancers containing both an intraductal and metaplastic subtype were derived from the same 
clonal population [5]. Using a similar approach, we show here that the ER positive and ER 
negative components of this patient’s primary tumor are derived from a common clonal 
origin. We discuss possible clinical implications of these findings below.
Materials and Methods
Case Report
Clinical History and Pathology Specimens—The patient is a 38 year old female who 
was diagnosed at an outside hospital with a T2N1 Grade 3 invasive ductal carcinoma (IDC) 
that was described as weakly ER positive on diagnostic biopsy, but was negative for ER/PR 
and HER2 receptors by immunohistochemistry staining on the surgical (lumpectomy) 
specimen. The pathology specimens were reviewed at Johns Hopkins Hospital and repeat 
stains on the surgical samples were performed and photographed. This study was carried out 
under an approved Institutional Review Board (IRB) protocol that allows for the use of 
remaining specimens for research purposes.
Tissue Processing and Nucleic Acid Extraction—Genomic DNA (gDNA) was 
isolated from formalin fixed paraffin embedded (FFPE) tissue using standard protocols. 
Briefly, H&E stained histology slides were examined by the study pathologist (P.A.) to 
identify areas of breast carcinoma. Ten to fifteen 5-micron thick unstained slides were 
deparaffinized and identified regions of interest were macrodissected using the Zymo pen 
and Pinpoint solution (Zymo Research, Irvine, CA), per the manufacturer’s protocol. DNA 
was then purified and isolated from the paired tumor samples using a QIAamp® DNA FFPE 
tissue kit (Qiagen, Valencia, CA), per the manufacturer’s protocol.
Whole Exome Sequencing and Analysis—Tumor DNA samples were submitted to 
Seqwright (Seqwright DNA Technology Services, Houston, TX) for next generation whole 
exome capture using the Agilent SureSelect 51 Mb Kit followed by next-generation 
sequencing using the Illumina Hi-Seq platform. The average read depths for the ER+ and 
ER− components were 86x and 90x, respectively.
A detailed description of the analysis pipeline is described elsewhere [5]. Briefly, we aligned 
paired end whole exome sequencing (WES) reads to the human reference genome 
(GRCh38) with BWA mem [6] with default parameters and called variants with GATK 
MuTect2 [7], using a panel of normals (PON) based on the ExAC [8] database. We required 
10 supporting reads for each base change in both tumor components and at least 4 reads for 
the alternative allele, and allele frequencies greater than 10%. We further annotated and 
filtered the variants with SnEff and SnpSift [9].
For copy number variant analysis, we used CNVkit (version 0.8.3) [10] to detect copy 
number variants, with the following parameteres: cnvkit.py batch [sorted bam file] —normal 
–targets [exome regions bed file] –fasta [GRCh38] –split –annotate [ftp://
hgdownload.cse.ucsc.edu/goldenPath//hg38/database/refFlat.txt.gz] –access [cnvkit-master/
data/access-10kb.hg38.bed] –output-reference [SAMPLE].cnn.
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Results
The breast specimen from the patient’s surgery was used for standard hematoxylin and eosin 
staining, as well as ER labeling as previously described [11]. As seen in Fig. 1A, the tumor 
had two distinct morphologies, with an area that was glandular, and a separate region that 
had a “solid” or uniform area of tumor cells. A serial section was stained for ER, and this 
showed the glandular component had strong ER labeling, while the solid area was 
completely negative for ER labeling (Fig. 1B). This raised the intriguing possibility that 
these distinct ER expressing cells and histologic subtypes were either derived from a 
common precursor, or as an alternative explanation, they were derived from separate clones 
that happened to be adjacent to one another. To address these possibilities, we chose to 
separately analyze these tumors at a genetic level with WES, similar to our prior work with 
primary breast tumors containing both an invasive ductal and metaplastic component [5].
The fundamental rationale of our approach is that tumors derived from the same clonal 
origin would share many genetic/genomic alterations including single nucleotide variants 
(SNV), and copy number variants (CNV) and that these would be shared at the same level 
for both “driver” and “passenger” mutations, i.e. alterations that would or would not, 
respectively, be expected to impart any functional consequence. Conversely, if clones were 
separately derived, it would be highly unlikely for the two components to share passenger 
mutations as well as driver mutations, as passenger mutations would be quickly gained 
separately once the clones diverged. For the purposes of distinguishing driver from 
passenger variants, we categorized SNVs as low (likely passenger mutations), moderate or 
high (likely driver mutations) impact based upon established criteria as described in our past 
studies [5, 12]. As shown in Fig. 2, the two separate ER positive and ER negative 
components shared a large number of SNVs, most of which were in the low impact category, 
i.e. passenger alterations. Although normal germline DNA was unavailable for controls, we 
employed a “panel of normal” encompassing > 60,000 normal genomes from the ExAC 
project, which we have used in past studies to filter out likely benign single nucleotide 
polymorphisms and variants [12]. Even after filtering with our panel of normals, the vast 
majority of variants were shared between the two distinct components. While shared SNVs 
after filtering with our panel of normals generally did not have the same allelic frequencies 
(Supplemental Fig. 1), this could be the result of contamination from normal gDNA within 
the tissue specimens. Given the number of shared SNVs, our data strongly suggest that the 
ER positive and negative components were derived from the same clonal origin.
Somatic copy number changes can also be assessed to infer clonality, similarly to SNVs. As 
shown in Fig. 3, circus plots demonstrated that the majority of copy number changes, 
whether gains or losses, were found in both ER components of the tumor. These data further 
support the notion that a common clone gave rise to both ER positive and negative 
components of the primary tumor.
Discussion
Systemic treatment for ER positive tumors generally involves the use of endocrine therapies, 
which are not used for ER negative tumors. Therefore, it is critical to assess receptor status 
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for all breast cancers as expression of ER greatly influences clinical management of the 
disease. The case report presented here has a number of clinical implications. First, we show 
that discrete separate regions of ER expression can exist within the same primary tumor. 
This could lead to sampling error where only a single component is assayed for ER 
expression, potentially missing an opportunity for using endocrine therapies if the ER 
positive component was not assessed. Second, the existence of a completely triple negative 
component (ER/PR/HER2 negative) generally mandates consideration for chemotherapy in 
the adjuvant and metastatic settings. Had the ER positive component been the only area 
assessed, one may have considered omitting adjuvant chemotherapy depending on other 
clinical and pathologic features. Third, from our molecular analysis, it is clear that ER 
negative tumors can be derived from ER positive cancer cells. Although this is likely to be 
an uncommon event based upon the now known mutational landscape of ER positive versus 
ER negative tumors [13], the findings here support that this is a possibility. Interestingly, we 
did not find any genetic alterations in ER (supplemental Table S1) that might explain the 
loss of ER expression, and opine that epigenetic silencing is likely the cause of this finding 
based upon past preclinical studies [14]. Whether the gene expression changes of these 
tumors reflect “classic” intrinsic subtypes for ER and TNBC, i.e. luminal and basal, remains 
uncertain and unfortunately, we did not have additional adequate sample material to perform 
these analyses. One could speculate however, that the ER positive component may be a more 
aggressive luminal B phenotype, while the receptor negative component may still give a 
“luminal” signature as has been described in the past for TNBC, which interestingly have a 
mutation profile more similar to ER positive tumors than classic basal TNBC [15]. 
Nonetheless, our study demonstrates the need for vigilance when assessing receptor status 
and that surveying multiple components of a primary tumor may be warranted in certain 
circumstances.
Conclusion
We describe a case report of an early stage breast cancer with two histologic components, 
one that is ER positive and the other ER negative. Genetic analyses using whole exome 
sequencing demonstrates that these two components were derived from the same clonal 
origin, suggesting that despite the differing histologies and receptor status, the patient did 
not have two independent primary tumors, which may have broader implications for therapy.
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Figure 1. A primary breast tumor with separate regions of ER positive and negative expression
A) Hematoxylin and eosin staining demonstrating distinct histologies with a glandular 
pattern on the left and a more solid phenotype on the right. B) Serial section of the same 
tumor showing ER labeling in the glandular component, but no labeling in the solid region 
to the right. 100x magnification.
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Figure 2. Variants shared between the ER positive and ER negative components of a primary 
breast tumor
Each stacked bar represents the percent allele sharing in the high, moderate (mod), low, 
modifier (modf), panel of normal (pon) and valid categories (where valid represents all 
categories not excluded by the panel of normals). Variants shared between the two 
components are represented in light blue. Y axis represent the number of variants.
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Figure 3. Copy number variation (CNV) segments in the ER positive and ER negative 
components of a primary breast tumor are similar
Circus plot depicting CNV from the two ER components in concentric rings. The ER 
positive component is depicted in the outer ring, while the ER negative component is shown 
the inner ring. Copy number gains are displayed in red and losses are displayed in blue. 
Each chromosome is denoted on the outer ring.
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